Veltrix's eczema pill clears skin in mid-stage trial
About 44% of patients on the highest dose reached clear or almost clear skin after 16 weeks, a result that keeps the company in a crowded race for an oral alternative to injections.
By Lena FischerPublished · 1 min read
Veltrix said Friday that its experimental pill for moderate-to-severe atopic dermatitis met the main goal of a Phase 2 study, clearing skin in a significantly larger share of patients than placebo.
At the highest of three doses tested, 44% of participants had clear or almost clear skin after 16 weeks, compared with 11% of those given a placebo. Itch scores improved within the first two weeks.
The safety picture was less tidy. Acne and headache were the most common side effects, and 6% of patients on the top dose stopped treatment early. Veltrix reported no blood clots or serious infections, the events that have weighed on older oral drugs for the condition.
The company plans to start two Phase 3 trials in the first half of next year. Shares rose 9% in morning trading.
